Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMBARISH PANDEY

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1891084729
CMS profile
4224976
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$161,537.55

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMBARISH PANDEY

NPI 1891084729 · CMS profile ID 4224976

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891084729?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMBARISH PANDEY, NPI 1891084729, CMS profile ID 4224976. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891084729?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AMBARISH PANDEY, NPI 1891084729, CMS profile ID 4224976. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891084729?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AMBARISH PANDEY, NPI 1891084729, CMS profile ID 4224976, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1891084729?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $161,537.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $60.2901/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186486299 CMS
Eli Lilly and Company $24.7701/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186486301 CMS
Eli Lilly and Company $15.5401/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186493565 CMS
Eli Lilly and Company $311.5801/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186504325 CMS
Eli Lilly and Company $18.1301/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186504327 CMS
Eli Lilly and Company $2.9901/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186504897 CMS
Eli Lilly and Company $12.6101/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186504899 CMS
Eli Lilly and Company $54.9301/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186508617 CMS
Eli Lilly and Company $34.4901/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186511585 CMS
Eli Lilly and Company $4.9901/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186511587 CMS
Eli Lilly and Company $5.9901/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186511589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $40,717.44 27
PY2023 $50,228.37 45
PY2024 $72,368.30 46
PY2025 $161,537.55 111

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,364,487.95 154
PY2024 Recipient $3,800.00 2
PY2024 Principal investigator $577,820.67 13
PY2023 Recipient $98,210.75 5
PY2023 Principal investigator $46,673.45 45
PY2022 Recipient $117,118.34 12
PY2022 Principal investigator $496,833.23 587
PY2021 Recipient $173,268.52 14
PY2021 Principal investigator $52,000.00 1
PY2020 Principal investigator $65,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

154 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $750.00 12/22/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
EX9536-4665 No dispute reported 06/30/2026 1213710997
Principal investigator 1 Edwards Lifesciences Corporation $3,350.00 12/16/2025 Non-covered Recipient Entity
The University Of Texas Southwestern Medical Center
ALT-FLOW II 2022-06 No dispute reported 06/30/2026 1222708156
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 12/15/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634357
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 12/15/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634359
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 12/15/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634361
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634351
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634353
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 12/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634355
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634339
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634341
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634343
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634345
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634347
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 11/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634349
Principal investigator 1 Roche Diagnostics Corporation $279,788.00 11/19/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007183: STRONG-DM: Evaluation of a pragmatic NT-ProBNP-based heart failure screening strategy among patients with type 2 diabetes: STRONG-DM Study No dispute reported 06/30/2026 1189190763
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994691
Principal investigator 1 Roche Diagnostics Corporation $25,000.00 11/07/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007626: BEACON-HF: NTproBNP Evaluation and Care Outcomes in Heart Failure No dispute reported 06/30/2026 1189190765
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634335
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634337
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634279
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634281
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634283
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634285
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634287
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634289
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634291
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634293
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634295
Principal investigator 1 Boehringer Ingelheim International GmbH $2,817.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634297
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634299
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634301
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634303
Principal investigator 1 Boehringer Ingelheim International GmbH $2,771.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634305
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634307
Principal investigator 1 Boehringer Ingelheim International GmbH $2,817.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634309
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634311
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634313
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634315
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634317
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634319
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634321
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634323
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634325
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634327
Principal investigator 1 Boehringer Ingelheim International GmbH $293.00 10/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634329
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 10/02/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634331
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 10/02/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634333
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634275
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634277
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 09/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994689
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634141
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634199
Principal investigator 1 Boehringer Ingelheim International GmbH $499.50 08/26/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634155
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 08/26/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634157
Principal investigator 1 Boehringer Ingelheim International GmbH $7.83 08/26/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634159
Principal investigator 1 Boehringer Ingelheim International GmbH $11.28 08/26/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634161
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 08/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634193
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 08/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634195
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 08/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634197
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $13,353.92 08/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994687
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634189
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634191
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 07/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634179
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 07/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634181
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 07/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634185
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 07/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634187
Principal investigator 1 Boehringer Ingelheim International GmbH $250.00 07/11/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634183
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634231
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634233
Principal investigator 1 Roche Diagnostics Corporation $67,601.00 07/01/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007183: STRONG-DM: Evaluation of a pragmatic NT-ProBNP-based heart failure screening strategy among patients with type 2 diabetes: STRONG-DM Study No dispute reported 06/30/2026 1189190761
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634153
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634225
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634227
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634229
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634251
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634253
Principal investigator 1 Boehringer Ingelheim International GmbH $1,955.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634255
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634257
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634259
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634261
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634263
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 06/20/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634265
Principal investigator 1 Amgen Inc. $27,916.22 06/08/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246650884
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634235
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634237
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634239
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634241
Principal investigator 1 Boehringer Ingelheim International GmbH $2,475.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634243
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634245
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634247
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634249
Principal investigator 1 Boehringer Ingelheim International GmbH $3,286.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634271
Principal investigator 1 Boehringer Ingelheim International GmbH $1,955.00 06/04/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634273
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634267
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634269
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 05/28/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994685
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 05/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634147
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 05/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634149
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 05/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634151
Principal investigator 1 Roche Diagnostics Corporation $55,000.00 05/25/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007183 STRONG-DM: Evaluation of a pragmatic NT-ProBNP-based heart failure screening strategy among patients with type 2 diabetes: STRONG-DM Study No dispute reported 06/30/2026 1189190759
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634115
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634117
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634095
Principal investigator 1 Boehringer Ingelheim International GmbH $3,286.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634097
Principal investigator 1 Boehringer Ingelheim International GmbH $3,286.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634099
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634101
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634103
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634105
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634107
Principal investigator 1 Boehringer Ingelheim International GmbH $279.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634109
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634111
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 04/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634113
Principal investigator 1 Boehringer Ingelheim International GmbH $3.10 04/23/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634143
Principal investigator 1 Boehringer Ingelheim International GmbH $28.20 04/23/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634145
Principal investigator 1 Boehringer Ingelheim International GmbH $659.34 04/23/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634215
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 04/23/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634217
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 04/23/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634219
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,288.43 04/23/2025 Non-covered Recipient Entity
University Of Texas Southwestern Medical Center
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235992351
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 04/17/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994683
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $43,871.25 04/08/2025 Non-covered Recipient Entity
University Of Texas Southwestern Medical Center
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF) No dispute reported 06/30/2026 1235992353
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634119
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634121
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11,684.68 03/21/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994681
Principal investigator 1 Boehringer Ingelheim International GmbH $1,478.00 03/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634125
Principal investigator 1 Boehringer Ingelheim International GmbH $226.00 03/19/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634127
Principal investigator 1 Edwards Lifesciences Corporation $10,050.00 03/03/2025 Non-covered Recipient Entity
The University Of Texas Southwestern Medical Center
ALT-FLOW II 2022-06 No dispute reported 06/30/2026 1222708092
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634137
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634139
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634129
Principal investigator 1 Boehringer Ingelheim International GmbH $121.00 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634131
Principal investigator 1 Boehringer Ingelheim International GmbH $1,955.00 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634133
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634135
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634207
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634209
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634211
Principal investigator 1 Boehringer Ingelheim International GmbH $7.52 02/25/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634213
Principal investigator 1 ROCHE DIAGNOSTICS INTERNATIONAL LTD $20,000.00 02/19/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
SUB-001830 No dispute reported 06/30/2026 1250349176
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634175
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634177
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634123
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 01/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634201
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 01/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634203
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 01/27/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634205
Principal investigator 1 Boehringer Ingelheim International GmbH $188.00 01/24/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634173
Principal investigator 1 Boehringer Ingelheim International GmbH $3,286.00 01/22/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634163
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 01/22/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634165
Principal investigator 1 Boehringer Ingelheim International GmbH $2,561.00 01/22/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634167
Principal investigator 1 Boehringer Ingelheim International GmbH $1,955.00 01/22/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634169
Principal investigator 1 Boehringer Ingelheim International GmbH $2,699.00 01/22/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634171
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 01/13/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994679
Principal investigator 1 Roche Diagnostics Corporation $332,266.00 01/08/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007019_ACCORD-BP:Biomarker Guided Cardiovascular Risk Prediction among patients with Type 2 Diabetes in the ACCORD Trial No dispute reported 06/30/2026 1189190757
Principal investigator 1 Roche Diagnostics Corporation $339,327.00 01/07/2025 Non-covered Recipient Entity
The University of Texas Southwestern Medical Center
RD007019_ACCORD-BP:Biomarker Guided Cardiovascular Risk Prediction among patients with Type 2 Diabetes in the ACCORD Trial No dispute reported 06/30/2026 1189190755
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634221
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
UT Southwestern Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220634223